burnin1
Well-Known Member
From leafly.com
The Bayer-Monsanto Deal Wont Eat the Cannabis Industry. Yet.
By Paul Roberts
The news that Monsanto is being bought by Bayer probably wont be well received in the cannabis sector. The deal brings together two research powerhouses that, reportedly, have long eyed cannabis as a possible new business. The worry is that the combined firm will have the financial and political influence to do to cannabis what it has already done to corn, tobacco, and other cash cropsnamely, use pricy patented cannabis seeds (Roundup Ready Blue Dream, anyone?) that favor large-scale operators and rigidly control how all cannabis farmers farm. The merger, in other words, could be the first step toward Big Cannabis.
In truth, its far from certain just how worried small cannabis should be. On the one hand, Bayer clearly has designs on the multi-billion-dollar cannabis market. The German firm has been working with GW Pharmaceuticals on a cannabis-based medicinal extract since 2003. And while Monsanto says it has not and is not working on GMO marijuana, the company will soon enjoy access to Bayers cannabis expertise, which, given Monsantos control-through-litigation tactics, might lead one to imagine some pretty bleak scenarios.
That said, its hardly clear that this merger makes those scenariosor Big Cannabis generallyany more plausible.
First, as a practical matter, the merger itself is still just a theory. Monsantos shareholders accepted Bayers $66 billion buyout offer, but the mega-deal needs approval from American and German regulators. And given the firms massive market share (it would control more than a quarter of the worlds seed and fertilizer business) on top of strong antitrust sentiment worldwide, that approval is hardly assured. And, as a side note, 60 to 80 percent of all mergers fail.
Second, even if approved, a Bayer-Monsanto enterprise likely wouldnt launch a cannabis product until federal prohibition is lifted. Its the same reason Big Tobacco hasnt completely taken over cannabis, despite a decades-old interest in doing so: Massive corporations need massive volume sales, which, in the case of cannabis, is hard to do without a fully open national marketplace. Yes, some in Big Pharma are now reportedly lobbying in favor of legalizationbut theres hardly a sector-wide consensus, as the recent anti-legalization effort by Insys Therapeutics underscores.
Third, even if the feds legalized cannabis tomorrow, a Bayer-Monsanto mega-corporation probably wont result in any retail cannabis products for some time. Its true that Bayer has already partnered with pharmaceutical firms that are doing trials of cannabis drugs. Also, Monsanto may be less than candid when it says it hasnt (yet) tinkered with cannabiss genetics. But however far along their respective cannabis research efforts are, turning research into commercial product takes years, especially in a market as heavily regulated and politically fragmented as cannabis will continue to be.
Fourth, when it comes to the rise of Big Cannabis, a Bayer-Monsanto merger would merely add to a process that is already well underway. The seed and drug industries are hardly the first mainstream sectors to try to colonize cannabis. Since the start of state legalization, nearly every outside industry with a conceivable cannabis playtobacco of course, but also food and beverage, clothing, health & wellness, tourism, and Silicon Valley venture capitalhas been scrambling to bring the cannabis sector out of the margins and into the mainstream.
More to the point, as the cannabis community itself has matured, it has been moving incrementally toward a business model that, if one didnt know better, looks surprisingly corporate. For example, with competitive pressures squeezing retail margins, a steady stream of independent retailers have been selling out to larger, more cost-efficient retail chains. This is especially the case in Colorado. Likewise, in a mirror image of the larger faming business, struggling small-scale cannabis farms are being consolidated into larger scale operations whose managers (and investors) are anxiously adopting any method, or technology, that might help them boost output and lower costs. Five or ten years from now, will those farms turn their noses up at a genetically engineered cannabis strain that promises more bang for the buck? More to the point, will their customers?
And therein lies the rub. It may be tempting to see mergers like this one as a threat to the traditional cannabis community, a culture that values a diverse mix of independent small-scale operators. Make no mistake: A merger of this magnitude does promise big changes for global agriculture. But in a cannabis sector that is looking more and more like any other consumer sector, the larger factor may the changing priorities of the cannabis consumer. In the end, the customers dollar determines which productsand companiessucceed or fail.
https://www.leafly.com/news/industry/bayer-monsanto-deal-wont-eat-cannabis-industry-yet/
The Bayer-Monsanto Deal Wont Eat the Cannabis Industry. Yet.
By Paul Roberts
The news that Monsanto is being bought by Bayer probably wont be well received in the cannabis sector. The deal brings together two research powerhouses that, reportedly, have long eyed cannabis as a possible new business. The worry is that the combined firm will have the financial and political influence to do to cannabis what it has already done to corn, tobacco, and other cash cropsnamely, use pricy patented cannabis seeds (Roundup Ready Blue Dream, anyone?) that favor large-scale operators and rigidly control how all cannabis farmers farm. The merger, in other words, could be the first step toward Big Cannabis.
In truth, its far from certain just how worried small cannabis should be. On the one hand, Bayer clearly has designs on the multi-billion-dollar cannabis market. The German firm has been working with GW Pharmaceuticals on a cannabis-based medicinal extract since 2003. And while Monsanto says it has not and is not working on GMO marijuana, the company will soon enjoy access to Bayers cannabis expertise, which, given Monsantos control-through-litigation tactics, might lead one to imagine some pretty bleak scenarios.
That said, its hardly clear that this merger makes those scenariosor Big Cannabis generallyany more plausible.
First, as a practical matter, the merger itself is still just a theory. Monsantos shareholders accepted Bayers $66 billion buyout offer, but the mega-deal needs approval from American and German regulators. And given the firms massive market share (it would control more than a quarter of the worlds seed and fertilizer business) on top of strong antitrust sentiment worldwide, that approval is hardly assured. And, as a side note, 60 to 80 percent of all mergers fail.
Second, even if approved, a Bayer-Monsanto enterprise likely wouldnt launch a cannabis product until federal prohibition is lifted. Its the same reason Big Tobacco hasnt completely taken over cannabis, despite a decades-old interest in doing so: Massive corporations need massive volume sales, which, in the case of cannabis, is hard to do without a fully open national marketplace. Yes, some in Big Pharma are now reportedly lobbying in favor of legalizationbut theres hardly a sector-wide consensus, as the recent anti-legalization effort by Insys Therapeutics underscores.
Third, even if the feds legalized cannabis tomorrow, a Bayer-Monsanto mega-corporation probably wont result in any retail cannabis products for some time. Its true that Bayer has already partnered with pharmaceutical firms that are doing trials of cannabis drugs. Also, Monsanto may be less than candid when it says it hasnt (yet) tinkered with cannabiss genetics. But however far along their respective cannabis research efforts are, turning research into commercial product takes years, especially in a market as heavily regulated and politically fragmented as cannabis will continue to be.
Fourth, when it comes to the rise of Big Cannabis, a Bayer-Monsanto merger would merely add to a process that is already well underway. The seed and drug industries are hardly the first mainstream sectors to try to colonize cannabis. Since the start of state legalization, nearly every outside industry with a conceivable cannabis playtobacco of course, but also food and beverage, clothing, health & wellness, tourism, and Silicon Valley venture capitalhas been scrambling to bring the cannabis sector out of the margins and into the mainstream.
More to the point, as the cannabis community itself has matured, it has been moving incrementally toward a business model that, if one didnt know better, looks surprisingly corporate. For example, with competitive pressures squeezing retail margins, a steady stream of independent retailers have been selling out to larger, more cost-efficient retail chains. This is especially the case in Colorado. Likewise, in a mirror image of the larger faming business, struggling small-scale cannabis farms are being consolidated into larger scale operations whose managers (and investors) are anxiously adopting any method, or technology, that might help them boost output and lower costs. Five or ten years from now, will those farms turn their noses up at a genetically engineered cannabis strain that promises more bang for the buck? More to the point, will their customers?
And therein lies the rub. It may be tempting to see mergers like this one as a threat to the traditional cannabis community, a culture that values a diverse mix of independent small-scale operators. Make no mistake: A merger of this magnitude does promise big changes for global agriculture. But in a cannabis sector that is looking more and more like any other consumer sector, the larger factor may the changing priorities of the cannabis consumer. In the end, the customers dollar determines which productsand companiessucceed or fail.
https://www.leafly.com/news/industry/bayer-monsanto-deal-wont-eat-cannabis-industry-yet/
